In 1909 Paul Ehrlich postulated that the immune system may defend the host against neoplastic cells and hinder the development of cancers. This concept has been widely recognized ever since, and eventually led to the development of novel cancer treatments in more recent years that revolutionized canc...
Here, we propose a method to prepare neoantigen-reactive T cells (NRT) for ACT following immunization with a tumor lysate-loaded dendritic cell (DC) vaccine. We show that the DC vaccine not only induces a neoantigen-reactive immune response in lung cancer-bearing mice in vivo, but also ...
DCOne is a cell based tumor vaccine derived from an acute myelogenous leukemia cell line, differentiated toward a dendritic cell (DC) phenotype (DCPrime, Netherlands). DCOne strongly expresses WT-1, PRAME, RHAMM, survivin, and MUC-1. Since MM cells commonly express these tumor-associated ...
Initiate anti-cancer immunity: releasing of cancer cell antigen, cancer antigen presentation, and priming and activation. Tumor cell death is accompanied by antigen release. Dendritic cells present antigens to naïve T cells. Then, the naïve T cells prime and activate the effector T cells. On...
Development of a Dendritic Cell (DC) Vaccine for Advanced Colorectal Cancerdoi:10.1007/978-1-4615-0547-1_23Colorectal cancer is one of the most common malignancies encountered in the Western World and in-spite of the development of treatment strategies involving adjuvant chemotherapy, hepatic ...
constructed a structurally well-defined DNA-based nanodevice to quantitatively assemble cancer cell-specific antigen and multiple adjuvants as a cancer vaccine. This nanodevice vaccine can efficiently accumulate in the draining lymph nodes and respond to the endosomal acidic environment of dendritic cells ...
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen […]. Science 2015; 348: 803–808 None - 《Tumordiagn U Ther》 被引量: 0发表: 2015年 T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo ...
In this study we investigate whether the addition of an autologous dendritic cell (DC) based cancer vaccine provokes an immune response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel based chemotherapy. Methods 43 patients were randomized 1:1 to receive...
Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical
Dendritic cell (DC) vaccination has been shown to induce anti-tumour immune responses in cancer patients, but so far its clinical efficacy is limited. Recent evidence supports an immunogenic effect of cytotoxic chemotherapy. Pre-clinical data indicate th